Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. / Mortensen, Martin Bødtker; Nordestgaard, Børge Grønne.
In: Annals of Internal Medicine, Vol. 168, No. 2, 2018, p. 85-92.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population
AU - Mortensen, Martin Bødtker
AU - Nordestgaard, Børge Grønne
PY - 2018
Y1 - 2018
N2 - Background: Five major organizations recently published guidelines for using statins to prevent atherosclerotic cardiovascular disease (ASCVD): in 2013, the American College of Cardiology/American Heart Association (ACC/AHA); in 2014, the United Kingdom's National Institute for Health and Care Excellence (NICE); and in 2016, the Canadian Cardiovascular Society (CCS), the U.S. Preventive Services Task Force (USPSTF), and the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS).Objective: To compare the utility of these guidelines for primary prevention of ASCVD.Design: Observational study of actual ASCVD events during 10 years, followed by a modeling study to estimate the effectiveness of different guidelines.Setting: The Copenhagen General Population Study.Participants: 45 750 Danish persons aged 40 to 75 years who did not use statins and did not have ASCVD at baseline.Measurements: The number of participants eligible to use statins according to each guideline and the estimated number of ASCVD events that statins could have prevented.Results: The percentage of participants eligible for statins was 44% by the CCS guideline, 42% by ACC/AHA, 40% by NICE, 31% by USPSTF, and 15% by ESC/EAS. The estimated percentage of ASCVD events that could have been prevented by using statins for 10 years was 34% for CCS, 34% for ACC/AHA, 32% for NICE, 27% for USPSTF, and 13% for ESC/EAS.Limitation: This study was limited to primary prevention in white Europeans.Conclusion: Guidelines recommending that more persons use statins for primary prevention of ASCVD should prevent more events than guidelines recommending use by fewer persons.Primary Funding Source: Copenhagen University Hospital.
AB - Background: Five major organizations recently published guidelines for using statins to prevent atherosclerotic cardiovascular disease (ASCVD): in 2013, the American College of Cardiology/American Heart Association (ACC/AHA); in 2014, the United Kingdom's National Institute for Health and Care Excellence (NICE); and in 2016, the Canadian Cardiovascular Society (CCS), the U.S. Preventive Services Task Force (USPSTF), and the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS).Objective: To compare the utility of these guidelines for primary prevention of ASCVD.Design: Observational study of actual ASCVD events during 10 years, followed by a modeling study to estimate the effectiveness of different guidelines.Setting: The Copenhagen General Population Study.Participants: 45 750 Danish persons aged 40 to 75 years who did not use statins and did not have ASCVD at baseline.Measurements: The number of participants eligible to use statins according to each guideline and the estimated number of ASCVD events that statins could have prevented.Results: The percentage of participants eligible for statins was 44% by the CCS guideline, 42% by ACC/AHA, 40% by NICE, 31% by USPSTF, and 15% by ESC/EAS. The estimated percentage of ASCVD events that could have been prevented by using statins for 10 years was 34% for CCS, 34% for ACC/AHA, 32% for NICE, 27% for USPSTF, and 13% for ESC/EAS.Limitation: This study was limited to primary prevention in white Europeans.Conclusion: Guidelines recommending that more persons use statins for primary prevention of ASCVD should prevent more events than guidelines recommending use by fewer persons.Primary Funding Source: Copenhagen University Hospital.
KW - Adult
KW - Aged
KW - Atherosclerosis/epidemiology
KW - Denmark/epidemiology
KW - Female
KW - Guideline Adherence
KW - Humans
KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
KW - Male
KW - Middle Aged
KW - Practice Guidelines as Topic
KW - Primary Prevention
KW - Prospective Studies
KW - Societies, Medical
U2 - 10.7326/M17-0681
DO - 10.7326/M17-0681
M3 - Journal article
C2 - 29297004
VL - 168
SP - 85
EP - 92
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
SN - 0003-4819
IS - 2
ER -
ID: 218723996